The stock market recorded stellar year-end returns when markets closed on Wednesday for the last time in 2025. The performance marked three straight years
Latest News
Tech stocks outshine rest of stock market again in 2025
Communication-services stocks were on pace to be the stock index’s top-performing sector in back-to-back years, according to Dow Jones Market Data. It was poised
Stock Market Today, Dec. 31: Plug Power Rises After Clear Street Upgrades Rating Despite Lower Price Target
Today, Dec. 31, 2025, a cautious analyst upgrade spotlights Plug Power’s high‑risk hydrogen turnaround and funding puzzle.
Stock Market Today, Dec. 31: Lackluster Year End Barely Dents 2025’s Double Digit Gains
On Dec. 31, 2025, profit‑taking in high‑growth names and fading AI buzz dragged major U.S. benchmarks lower into a thin year‑end close.
These Are Some Of My Favorite Investment Picks For 2026
Selective stock picking may outperform broad market exposure amid high valuations and AI-driven earnings forecasts. Read more here.
Dow Jones futures: Market tests key levels to end 2025; Tesla, Palantir, Nvidia chipmaker in focus
The stock market fell to end a solid 2025. Palantir and Nvidia chipmaker Taiwan Semi were in focus. Tesla deliveries loom.
BALI: Income Returns On S&P 500 Growth
In general, BALI can be used as a replacement for an investment in the S&P 500 ( IVV) given the similar return profile. Despite
ChatGPT predicts S&P 500 index for the end of 2026
As the U.S. equity market closes 2025 near record levels, attention is already shifting to what the next year may hold for the S&P
Stock Market Live December 31: Decent Jobs Numbers Help S&P 500 (VOO) Gain on New Year’s Eve
Live Updates Get The Best Vanguard S&P 500 ETF Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on Vanguard
US Stock Market Today: S&P 500 and NASDAQ 100 Trade Flat as Jobless Claims Decline and Dollar Struggles
Single-stock moves reflected event-driven trading. Vanda Pharmaceuticals surged after the US FDA approved its motion-sickness treatment tradipitant. Axsome Therapeutics jumped after its Alzheimer’s drug